415 related articles for article (PubMed ID: 16258881)
1. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
2. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
4. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
5. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
6. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
7. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
8. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
9. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
10. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
12. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
[TBL] [Abstract][Full Text] [Related]
14. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
20. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K
Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
